The proxy contest outcome likely favors management given the dissidents' minimal stake and lack of relevant experience. The near-term catalyst is the upcoming 12-month data readout from the COVID-19 Sentinel Cohort, which could significantly impact the stock. Monitor for that data release and any further settlement developments.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $0.5700entry
- T+1 · 5mo ago +5.26%α +4.48% · $0.6000
- T+5 · 4mo ago +10.44%α +9.05% · $0.6295
- T+20 · 4mo ago −21.04%α −20.78% · $0.4501
- T+60 · 8w ago −14.04%α −17.08% · $0.4900
Price Chart
How similar events traded
Executive Summary
Vaxart filed an updated investor presentation as definitive additional proxy soliciting material, revising details on its $40M financing date, 2025 say-on-pay vote outcome (32.5% support), and rebutting dissident nominee qualifications. The filing is part of an ongoing proxy contest where management urges shareholders to vote FOR all six incumbent directors against a dissident slate holding 0.5% of shares. The company also highlights imminent 12-month safety/immunogenicity data from its BARDA-funded Phase 2b COVID-19 trial (400-subject Sentinel Cohort) and a $29M BARDA funding release, with cash runway into Q2 2027.
Key Financial Metrics
Key Facts
- Vaxart updated its investor presentation with revised information on the $40M financing date, 2025 say-on-pay vote outcome (32.5% support), and qualifications of dissident nominees Daniel Houle and Mark Silverberg.
- Company expects 12-month safety/immunogenicity data from the 400-participant Sentinel Cohort imminently and efficacy data from the ~5,100-participant Main Cohort in H1 2027.
- BARDA released an additional $29M for trial completion, bringing total available funding to approximately $345M.
- Cash and cash equivalents were $61M as of March 31, 2026, providing runway into Q2 2027.
- Board unanimously recommends voting FOR all six director nominees; dissident group holds approximately 0.5% of outstanding shares.
- Dissident nominees lack public company board experience, clinical-stage biotech expertise, and have not presented credible value-creation ideas.
Financial Impact
No new financial data in this filing; previously disclosed $29M additional BARDA funding and $345M total trial funding reiterated.
Risk Factors
- Dissident slate could win if retail shareholders vote for them, though unlikely given their small ownership and lack of qualifications.
- Clinical trial data may be negative or delayed, impacting the stock.
- Cash runway only into Q2 2027; additional financing may be needed if milestones are not met.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-072735 |
| Document: 0001213900-26-072735-index-headers.html | 0001213900-26-072735 |
| Document: 0001213900-26-072735-index.html | 0001213900-26-072735 |
| Document: 0001213900-26-072735.txt | 0001213900-26-072735 |
Track record
23 reports on VXRT
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
- Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
- Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
- Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
- Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
- Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
- Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 4/10 Viewing Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers